<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36223804</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-9064</ISSN><JournalIssue CitedMedium="Internet"><Volume>49</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Seminars in thrombosis and hemostasis</Title><ISOAbbreviation>Semin Thromb Hemost</ISOAbbreviation></Journal><ArticleTitle>COVID-19-Associated Pulmonary Embolism: Review of the Pathophysiology, Epidemiology, Prevention, Diagnosis, and Treatment.</ArticleTitle><Pagination><StartPage>816</StartPage><EndPage>832</EndPage><MedlinePgn>816-832</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0042-1757634</ELocationID><Abstract><AbstractText>COVID-19 is associated with endothelial activation in the setting of a potent inflammatory reaction and a hypercoagulable state. The end result of this thromboinflammatory state is an excess in thrombotic events, in particular venous thromboembolism. Pulmonary embolism (PE) has been of special interest in patients with COVID-19 given its association with respiratory deterioration, increased risk of intensive care unit admission, and prolonged hospital stay. The pathophysiology and clinical characteristics of COVID-19-associated PE may differ from the conventional non-COVID-19-associated PE. In addition to embolic events from deep vein thrombi, in situ pulmonary thrombosis, particularly in smaller vascular beds, may be relevant in patients with COVID-19. Appropriate prevention of thrombotic events in COVID-19 has therefore become of critical interest. Several changes in viral biology, vaccination, and treatment management during the pandemic may have resulted in changes in incidence trends. This review provides an overview of the pathophysiology, epidemiology, clinical characteristics, and risk factors of COVID-19-associated PE. Furthermore, we briefly summarize the results from randomized controlled trials of preventive antithrombotic therapies in COVID-19, focusing on their findings related to PE. We discuss the acute treatment of COVID-19-associated PE, which is substantially similar to the management of conventional non-COVID-19 PE. Ultimately, we comment on the current knowledge gaps in the evidence and the future directions in the treatment and follow-up of COVID-19-associated PE, including long-term management, and its possible association with long-COVID.</AbstractText><CopyrightInformation>Thieme. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ortega-Paz</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talasaz</LastName><ForeName>Azita H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadeghipour</LastName><ForeName>Parham</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Trial Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Potpara</LastName><ForeName>Tatjana S</ForeName><Initials>TS</Initials><AffiliationInfo><Affiliation>School of Medicine, University of Belgrade, Belgrade, Serbia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Intensive Arrhythmia Care, Cardiology Clinic, Clinical Center of Serbia, Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aronow</LastName><ForeName>Herbert D</ForeName><Initials>HD</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Warren Alpert Medical School of Brown University, Providence, Rhode Island.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Henry Ford Health, Detroit, Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jara-Palomares</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Respiratory Unit, Hospital Universitario Virgen del Rocio, Sevilla, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias (CIBERES), Carlos III Health Institute, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sholzberg</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angiolillo</LastName><ForeName>Dominick J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lip</LastName><ForeName>Gregory Y H</ForeName><Initials>GYH</Initials><AffiliationInfo><Affiliation>Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bikdeli</LastName><ForeName>Behnood</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yale/YNHH Center for Outcomes Research and Evaluation (CORE), New Haven, Connecticut.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Research Foundation (CRF), New York, New York.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Semin Thromb Hemost</MedlineTA><NlmUniqueID>0431155</NlmUniqueID><ISSNLinking>0094-6176</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="Y">Venous Thrombosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="Y">Thrombosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>L.O-P: Nothing to disclose.A.H.T.: Nothing to disclose.P.S.: Nothing to disclose.T.S.P.: Nothing to disclose.H.D.A.: Outside the submitted work, H.A.D. is a consultant for Silk Road Medical for Philips.L.J-P.: Grants from Leo Pharma and MSD and personal fees from Daichii, Rovi, GlaxoSmithKline, and Actellion outside the submitted work.M.S.: Co-principal investigator of the RAPID trial.D.J.A.: Consulting fees or honoraria from Abbott, Amgen, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, PhaseBio, PLx Pharma, Pfizer, and Sanofi. D.J.A. also declares that his institution has received research grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Idorsia, Janssen, Matsutani Chemical Industry Co., Merck, Novartis, Osprey Medical, Renal Guard Solutions, and the Scott R. MacKenzie Foundation.G.Y.H.L.: Consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, and Daiichi-Sankyo. No fees are received personally.B.B.: Reports that he is a consulting expert, on behalf of the plaintiff, for litigation related to two specific brand models of IVC filters.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>23</Day><Hour>12</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>12</Day><Hour>19</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36223804</ArticleId><ArticleId IdType="doi">10.1055/s-0042-1757634</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>